Cardiovascular Drugs Market - Changing Dietary Habits and Sedentary Lifestyle Trends to Boost the Market

Cardiovascular diseases (CVD’s) are the leading cause of deaths across the globe. According to World Health Organization’s report, more than 17.7 million individuals died of CVDs in 2015, and CVDs accounted for 31% of total deaths in 2013. Cardiovascular diseases are one of the leading cause for healthcare burden in developed as well as developing countries. Sedentary lifestyle, lack of exercise and changing dietary habits in developed and emerging markets is leading to cardiovascular diseases such as hypertension and hyperlipidemia which in turn is likely to fuel uptake of cardiovascular drugs. Many of the block buster cardiovascular drugs have lost their patent exclusivity in recent years and many are about to go off patent in near future. This factor has attracted many small and mid-size industry players to offer their generic drugs, which in turn has attributed for devaluation of the market, there by restraining growth of global cardiovascular drugs market.

Summary of the Report:

The report offers detailed segmentation of global cardiovascular drugs market based on drug class, indication and distribution channel. Among the drug class studied, anti-clotting agents segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. Anti-clotting agents segment which comprises anticoagulants and platelet aggregation inhibitors is likely to get boost from increasing incidences of heart failures, stroke, etc. According to Center for Disease Control and Prevention of the U.S., around 795,000 people in the U.S. suffer from a stroke each year of which 610,000 are found to be first or new cases of stroke. The renin-angiotensin system blockers segment is anticipated to lose its market share during the forecast period, and is expected to hold a share of ~16.0% by 2025 from ~18.0% in 2016. Availability of generics and adverse effects associated with ACE inhibitors and ARB’s are factors likely to hamper this segment.

Among indications, hypertension segment is projected to hold dominant share of global cardiovascular drugs market during the forecast period and is likely to expand at CAGR of around 1.5% from 2017 to 2025. Center for Disease Control and Prevention of the U.S. states that ~32% of adult population in the U.S. had high blood pressure in 2012. Surge in preference for hypertension specific drugs such as Tracleer, Letairis, etc. over conventional beta blockers, diuretics and calcium channel blockers is projected to fuel this expansion. Arrhythmia segment, which accounted for a meager share of global cardiovascular drugs market is anticipated to have substantial growth and account for approximately 4.0% of market share by 2025. Advancements in implantable cardiovascular devices such as leadless pacemakers, development of battery free pacemakers to treat arrhythmia is likely to hamper arrhythmia drugs market. Retail pharmacies are projected to be leading segment of distribution channel over the forecast period while online pharmacies are likely to register growth at CAGR of over 2.0% from 2017 to 2025. Adoption of e-commerce, convenience & discounts offered by mail pharmacies are major factors triggering this growth.

Get Sample PDF File:

In terms of value, North America was leading contributor in global cardiovascular drugs market in 2016. High prevalence of hyperlipidemia and hypertension in the U.S. is one of the contributing factor for major share of the North America market. However, increasing foray of generic drugs in the U.S. is implying pricing constraints on existing players which is likely to hamper this market. According to the Association for Accessible Medicines of the U.S., approximately 89% of the total prescriptions dispensed in 2016 in the U.S. were contributed by generic drugs. Healthcare spending in emerging markets such as China and India are rising, which is fueling the expansion of Asia Pacific cardiovascular drugs market. Regaining economic growth in Latin American markets such as Brazil is augmenting healthcare expenditure through rise in private health insurance, entry of international drug manufacturers and health care providers in this region. This factor is likely to propel Latin America cardiovascular drugs market at CAGR of 1.9% from 2017 to 2025.

The report also provide profiles of leading players operating in global cardiovascular drugs market include AstraZeneca plc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd. and Takeda Pharmaceutical Company Limited. Expansion of cardiovascular drugs portfolio through improving existing drugs and developing new drug molecules is one of the key strategy adopted by many key players, recent developments and launch of biological drugs such as PCSK9 for treating hyperlipidemia by Sanofi, Pfizer Inc. and other key players reflect these strategies.

Get Brochure:

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453